The impact of overall treatment time on the results of radiotherapy for nonsmall cell lung carcinoma

Angiogenesisvs. response after combined chemoradiotherapy of squamous cell head and neck cancer

“…This hypothesis is also supported by the observation that highly vascularized tumors (OMS Ͼ 50) had an up to 80% PR rate after chemotherapy, showing that although chemotherapy was effective, an interfering factor (which may be rapid cell repopulation) prevented tumor from being eliminated. In such tumors, the chemotherapy dose as well as the overall treatment time of radiotherapy may play important roles (Saunders et al, 1996;Koukourakis et al, 1996). Although the Fowler hypothesis of unmasked Tpot may underlay this process, the possibility of a real acceleration of clonogenic cell proliferation during radiotherapy in highly vascularized tumors cannot be excluded.…”

Cytoprotective Effect of Amifostine in Radiation-Induced Acute Mucositis – a Retrospective Analysis

“…The results of numerous phase I studies and a randomized phase II study have suggested that amifostine may protect against radiation-induced toxicity. On the basis of these results, a multi-institutional, international phase III trial of radiation therapy with and without amifostine in 315 patients with head and neck cancer was performed [26]. Standard fractionated radiation therapy (1.8-2.0 Gy/day for 5 days/week for 5-7 weeks, to a total dose of 50-70 Gy) was used in this study.…”

“…In this study, 28 patients received radiation therapy (up to a total dose of 60 Gy) in conjunction with carboplatin (70 mg/m 2 on days 1-5 and days [21][22][23][24][25][26]. At the completion of this trial, none of the amifostine-treated patients but 12 of 14 patients (86%) treated with radiation/chemotherapy alone experienced grade 3/4 mucositis (p = 0.0001).…”

High-dose Radiation Therapy alone for Inoperable Non-small cell Lung Cancer: Experience with Prolonged Overall Treatment Times

“…Repopulation of tumor clonogens during therapy has been considered to be responsible for these observations, although there still appears to be some controversial discussion in the literature (6). For nonsmall-cell carcinoma of the bronchus, there also exist indications that the time factor may play a role for outcome of radiation therapy (4,7,8). The time factor does probably not affect the entire treatment population, but only a subgroup of patients whose tumors have the potential for accelerated repopulation during therapy and who, therefore, would benefit from acceleration of treatment (9).…”